Call 413.540.1234 to
schedule an appointment
CONCERN/EAP: 413.534.2625
Billing questions? Call: 413.540.1212
CRISIS: 413.733.6661

Child Development & Parenting: Infants (0-2)
Resources
Basic Information
Infant Development: How Your Baby Grows and MaturesInfant Parenting: Keeping Your Baby Healthy and HappyInfant Safety: Keeping Your Baby SafeInfant Enrichment: Stimulating Your Baby
More InformationLatest News
Treatment for Teething Pain Poses Serious Health Threat: FDAFetal Growth, Maternal Anger Impact Infant RegulationInfants Know Real 'Baby Talk' When They Hear ItOpioid Crisis Means More Newborns With Hepatitis C, But Few Get TestedCCHD Newborn Screening May Detect Other DiseasesHealth Tip: Prevent Hand, Foot and Mouth DiseaseMultiple Anesthesia Exposures Affect Learning and AttentionHealth Tip: Milestones to Look for by Age 5Anesthesia Doesn't Seem to Harm Child's IQ: StudyHealth Tip: Prevent Poisoning at HomeHeath Tip; How to Introduce Your Child to PeanutsHealth Tip: When to See a Doctor for Cradle CapZika Infection After Birth May Require Long-Term Follow-UpRear-Facing Car Seats Protect Tots in Crashes From Behind: StudyBabies Given Certain Meds May Have Higher Odds for Allergies LaterHealth Tip: Which Car Seat Should Your Child Use?Baby Sitters, Relatives Often Unaware of SIDS RiskReading With Your Toddler Boosts More Than Just Language SkillsHealth Tip: Treat Diarrhea in Young BabiesNew Moms Still Wary of Exposing Infants to PeanutsHealth Tip: Use a High Chair SafelyPoison Prevention at HomeGenetic Heart Defects Rarely the Cause of SIDS, Research ShowsVaccine Exposure in First 23 Months Has No Adverse ImpactMechanical Heart Valve Approved for NewbornsMom's Immune System May Affect Baby's BrainVaccines Don't Weaken Babies' Immune Systems: StudyHealth Tip: Prevent Tooth Decay in BabiesPointers for Easier Potty TrainingHealth Tip: Make Sure Babies Eat RightGut Microbiota May Affect Vertical Transmission of Being OverweightHealth Tip: Protect Baby from Whooping CoughMany Parents in the Dark on When Kids Should First See a DentistStroke May Not Mean Language Loss for NewbornsCause of Sudden Unexpected Infant Deaths Shifts in the U.S.Babies Face Higher SIDS Risk in Certain StatesNICU Family Integrated Care Ups Infant, Parent OutcomesBabies With Normal Head Size Might Still Have Zika-Linked Brain DamageZika Tied to Rise in U.S. Birth Defects: CDCNutrients in Child's First 1,000 Days Key for NeurodevelopmentOpioid Epidemic Also Taking Toll on BabiesHome Visit Program Can Help Prevent Toddler ObesityHealth Tip: Succeed in Toilet TrainingNeurodevelopment Not Impacted by Glucocorticoids in PreemiesToo Many Babies Still Die Needlessly of SIDS, CDC Says16 Percent of Infants Receive Complementary Foods Too Early2013 to 2015 Infant Mortality Rate Varied by State and RaceHealth Tip: Health Tip: Prepare Your Child for the DentistMost U.S. Babies Start Solid Foods Too SoonSpecial Baby Formula Doesn't Seem to Prevent Type 1 Diabetes
Questions and AnswersLinks
Related Topics

Child & Adolescent Development: Overview
Childhood Mental Disorders and Illnesses
Parenting
Child Development & Parenting: Early (3-7)
Child Development & Parenting: Middle (8-11)

Neurodevelopment Not Impacted by Glucocorticoids in Preemies


HealthDay News
Updated: Jan 10th 2018

new article illustration

WEDNESDAY, Jan. 10, 2018 (HealthDay News) -- Use of inhaled glucocorticoids in extremely preterm infants for the prevention of bronchopulmonary dysplasia does not lead to a higher rate of neurodevelopmental disability at 2 years, according to a study published in the Jan. 11 issue of the New England Journal of Medicine.

Dirk Bassler, M.D., from University of Zurich, and colleagues randomly assigned 863 infants (gestational age, 23 weeks 0 days to 27 weeks 6 days) to receive early (within 24 hours after birth) inhaled budesonide or placebo. A long-term composite outcome of neurodevelopmental disability among survivors included cerebral palsy, cognitive delay (a Mental Development Index score of <85 on the Bayley Scales of Infant Development, Second Edition), deafness, or blindness at a corrected age of 18 to 22 months.

Based on follow-up data from 629 infants, the researchers found that 148 of 308 infants assigned to budesonide had neurodevelopmental disability versus 165 of 321 infants assigned to placebo (relative risk, adjusted for gestational age, 0.93; 95 percent confidence interval, 0.80 to 1.09; P = 0.40). For individual components of the composite outcome there was similarly no significant differences. However, there were more deaths among infants randomized to budesonide, compared to those given placebo (relative risk, 1.37; 95 percent confidence interval, 1.01 to 1.86; P = 0.04).

"We found no effect of budesonide on the risk of neurodevelopmental disability among surviving extremely preterm infants at 18 to 22 months of age," the authors write. "However, the mortality rate was higher in the budesonide group."

The research was funded by Chiesi Farmaceutici, which provided the study drugs free of charge.

Abstract/Full Text (subscription or payment may be required)